IBA and Jules Bordet Institute to lead IHI project Accelerate.EU to create complete Astatine-211 value chain
03 October 2024 - 3:00PM
UK Regulatory
IBA and Jules Bordet Institute to lead IHI project Accelerate.EU to
create complete Astatine-211 value chain
A EUR 16 million Initiative to Establish
Strategic EU Autonomy in Alpha Therapies for Cancer
Louvain-la-Neuve, Belgium,
October 3, 2024 – IBA (Ion Beam Applications S.A.,
EURONEXT), the world leader in particle accelerator technology and
the world’s leading provider of radiopharmaceutical production
solutions, is pleased to announce that the European Commission has
approved the financing of the Accelerate.EU project launching on
October 1, 2024. IBA’s key role in this new project further
reiterates its market leading role in supporting the production of
novel targeted alpha therapies for cancer.
As the industry leader of the Accelerate.EU
initiative, IBA will facilitate the development of a production
network to enable greater access to targeted alpha therapy across
the EU through the development of a new alpha-machine cyclotron as
an in-kind contribution. IBA will also work in close collaboration
with the Jules Bordet Institute, the academic and clinical
Accelerate.EU coordinator, to manage the project.
The Accelerate.EU project, a groundbreaking EUR
16 million initiative, has been officially launched with the
ambitious goal of establishing a resilient and strategic European
autonomy in alpha therapies. This five-year project aims to enhance
patient access to cutting-edge cancer treatments by creating a
complete value chain for the production and clinical application of
the alpha-emitting isotope Astatine-211 (211At).
The project has secured EUR 8 million in funding
from the European Commission under the Innovative Health Initiative
(IHI), matched by an equivalent in-kind contribution from industry
partners. This collaboration brings together 17 leading European
institutions and companies across 9 countries, blending academic
expertise with industrial innovation.
The Accelerate.EU project is set to transform
the landscape of cancer care by pioneering the development of novel
radiotheranostic solutions to address unmet clinical needs. At the
heart of this initiative is 211At, a highly promising
alpha-emitting radioisotope with the potential to treat aggressive
cancers such as triple-negative breast cancer, pancreatic cancer,
and glioblastoma. The project will focus on developing and testing
new therapeutic agents, ensuring a robust and sustainable
infrastructure for 211At production and treatment.
“By integrating the entire value chain—from
bench to bedside—Accelerate.EU aims to streamline the supply of
211At across Europe, ensuring that patients have timely
access to this innovative treatment. The project will also explore
co-clinical approaches, where clinical studies run in parallel with
preclinical studies, enhancing the ability to identify patients who
are most likely to benefit from 211At therapy. The
Accelerate.EU project is a significant step forward in cancer
research.” said Hugo Levillain, PhD, Project Lead
Coordinator at Institute Jules Bordet.
"As a global leader in particle accelerators,
IBA is proud to bring its expertise and advanced technology to this
transformative project. Accelerate.EU presents a unique opportunity
to push the boundaries of cancer treatment by developing
211At theranostics and accelerating the production and
clinical development. With the support of EU funding, we will equip
our partners with dedicated state-of-the-art production solutions,
offering hope to cancer patients with very limited treatment
options. We are proud that our market leading technology is playing
such an integral part in addressing the global demand for
radiopharmaceuticals." said Charles Kumps, President at IBA
RadioPharma Solutions.
About Accelerate.EU
The goal of Accelerate.EU is to establish a
stable and reliable cross-European supply chain for 211
At, ensuring broader availability and access to this promising
treatment. The project also aims to develop a cutting-edge
cyclotron and to enable the deployment of a distribution network to
produce 211At for hospitals.
As the project progresses, Accelerate.EU will
continue to produce comprehensive educational and training content
to support the deployment of these innovative solutions, ensuring
long-term knowledge dissemination and impact across Europe.
Acceletate.EU is supported by the Innovative
Health Initiative Joint Undertaking (IHI JU) under grant agreement
No [10173001]. The JU receives support from the European Union’s
Horizon Europe research and innovation programme and COCIR, EFPIA,
Europa Bío, MedTech Europe, and Vaccines Europe.
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 2,000 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance. IBA is listed on the
pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and
Bloomberg IBAB.BB). More information can be found at:
www.iba-worldwide.com
Olivier Lechien
Corporate Communication Director
+32 10 475 890
communication@iba-group.com
- 241003-IBA-and-Bordet-to-Lead-Accelerate.EU-EN
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
From Oct 2024 to Nov 2024
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
From Nov 2023 to Nov 2024